Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure

Medicine (United States)

Volumn 95, Issue 7, 2016, Pages e2760-

  Valbusa, Filippo ^a   Bonapace, Stefano ^a   Grillo, Cristina ^a   Scala, Luca ^a   Chiampan, Andrea ^a   Rossi, Andrea ^b   Zoppini, Giacomo ^b   Lonardo, Amedeo ^c   Arcaro, Guido ^a   Byrne, Christopher D ^d,e   Targher, Giovanni ^b  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c AUSL Modena   (Italy)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SARTAN DERIVATIVE; SPIRONOLACTONE; WARFARIN;

ACUTE HEART FAILURE; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPERTENSION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; COMPLICATION; HEART FAILURE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT READMISSION; PROSPECTIVE STUDIES;

EID: 84959115463     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002760     Document Type: Article

References (33)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
2. Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitali-zation for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391-403.
3. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418-1428.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344.
5. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
7. Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2015doi: 10.1016/j.metabol.2015.09.017 [Epub ahead of print].
8. Dhingra R, Gona P, Wang TJ, et al. Serum gamma-glutamyltransfer-ase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855-1860.
9. Wannamethee SG, Whincup PH, Shaper AG, et al. Gamma-glutamyl-transferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32:830-835.
10. Wang Y, Tuomilehto J, Jousilahti P, et al. Serum (-glutamyltransfer-ase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163-167.
11. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62:773-783.
12. Levey AS, Coresh J, Greene T, et al., Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
13. Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
14. Ballestri S, Romagnoli D, Nascimbeni F, et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol. 2015;9:603-627.
15. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. 2011;4:628-636.
16. Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010;3:726-745.
17. Blair JE, Pang PS, Schrier RW, et al., EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32:2563-2572.
18. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455-469.
19. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20:135-142.
20. Poelzl G, Eberl C, Achrainer H, et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail. 2009;2:294-302.
21. Décarie PO, Lepanto L, Billiard JS, et al. Fatty liver deposition and sparing: a pictorial review. Insights Imaging. 2011;2:533-538.
22. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58:757-762.
23. Pacifico L, Di Martino M, De Merulis A, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59:461-470.
24. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62:928-933.
25. Granér M, Nyman K, Siren R, et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging. 2015;8:e001979.
26. Mantovani A, Pernigo M, Bergamini C, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10:e0135329.
27. Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013;125:301-309.
28. Sinner MF, Wang N, Fox CS, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013;111:219-224.
29. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic Fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013;8:e57183.
30. Alonso A, Misialek JR, Amiin MA, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart. 2014;100:1511-1516.
31. Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost. 2013;39:214-228.
32. Armstrong MJ, Adams LA, Canbay A, et al. Extra-hepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174-1197.
33. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871.